Curative radiation therapy in prostate cancer

Authors

  • Ulrika Harmenberg Department of Oncology/Pathology, Karolinska University Hospital and Institutet, Stockholm, Sweden
  • Freddie C. Hamdy Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
  • Anders Widmark Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden
  • Bo Lennernäs Department of Oncology, Sahlgrenska Hospital and Academy, University of Gothenburg, Gothenburg, Sweden
  • Sten Nilsson Department of Oncology/Pathology, Karolinska University Hospital and Institutet, Stockholm, Sweden

DOI:

https://doi.org/10.3109/0284186X.2010.576115

Keywords:

Keywords:: Curative radiation therapy, the rationale for dose escalation, choice of radiation boost techniques

Abstract

Radiotherapy has experienced an extremely rapid development in recent years. Important improvements such as the introduction of multileaf collimators and computed tomography (CT)-based treatment planning software have enabled three dimensional conformal external beam radiation therapy (3DCRT). The development of treatment planning systems and technology for brachytherapy has been very rapid as well. Development of accelerators with integrated on-board imaging equipment and technology, for example image-guided radiation therapy (IGRT) has further improved the precision with reduced margins to adjacent normal tissues. This has, in turn, led to the possibility to administer even higher doses to the prostate than previously. Although radiotherapy and radical prostatectomy have been used for the last decades as curative treatment modalities, still there are no randomized trials published comparing these two options. Outcome data show that the two treatment modalities are highly comparable when used for low- and intermediate-risk prostate cancer.

Downloads

Download data is not yet available.

Downloads

Published

2011-06-01

How to Cite

Harmenberg, U., Hamdy, F. C., Widmark, A., Lennernäs, B., & Nilsson, S. (2011). Curative radiation therapy in prostate cancer. Acta Oncologica, 50(sup 1), 98–103. https://doi.org/10.3109/0284186X.2010.576115